Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Drugs 2014: OGD Creates Internal Review Goals, May Make OND-Inspired Changes

Executive Summary

In an interview, Acting Office of Generic Drugs Director Kathleen Uhl says reviewers need practice before the formal clock begins with October submissions.

You may also be interested in...



US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs

Implementer of many drug review changes will leave in January after nearly 32 years of public service.

Related Content

Topics

UsernamePublicRestriction

Register

PS055833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel